London-based marketing services provider Tangent Communications has agreed to acquire Newcastle-based direct marketing business Ravensworth and says the deal doubles its profits.
Tangent, which reversed onto AIM in 2005, provides sophisticated data-based services that improve the marketing efforts of a diverse and impressive range of clients, including SAP, Greene King, Coca Cola and Sainsbury’s. This is a fast-growing market segment.
One third of the business is devoted to customised direct marketing, another third to local-level marketing (through Tangent’s ‘Toolkit’ web system) and the final third to database building and management via the company’s first acquisition last July of C360, now re-branded Tangent Labs. This was completed for £4.5m and added a sophisticated tool and quality ex-Unilever management.
The purchase of Ravenswood for £5.85m has largely been funded by a £6.06m fundraising at 13p. It made £1.1m of profit from £6.9m sales in 2006, which effectively doubles group profits as Tangent was forecast by house broker Collins Stewart to make exactly the same amount in the year to February. Joint chief executive Nick Green says Ravensworth is ‘highly complementary’ and points out that its Newcastle headquarters has a large amount of excess capacity, allowing lots of room to expand operations away from high-cost London into the low-cost North East.
Tangent’s own business is going great guns anyway. For example, a contract was recently extended with leading construction materials supplier Wolseley’s UK arm to increase the supply of Tangent’s Toolkit system to 550 more centres on top of the 200 that had already been agreed.
Even before the acquisition, Collins Stewart had a prospective p/e of less than 15 on the figures to February 2007, falling to 12 times for the following year. That was good value, given the quality of new contract signings not yet factored in and the potential for growth.
Results are due out in the summer and Green revealed that current trading is in line with expectations. As the acquisition effectively doubles profits, the shares look too cheap. Buy.
Market cap: £14.81m
PE Forecast: 14.7
Share price: 13.25p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.